No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CNS240719P75000
- 0.82
- -1.27-60.77%
15min DelayClose Jul 16 16:00 ET
2.25High0.60Low
2.09Open2.09Pre Close100 Volume0 Open Interest75.00Strike Price11.14KTurnover102.68%IV8.46%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.82Extrinsic Value100Contract SizeAmericanOptions Type-0.1841Delta0.0360Gamma104.57Leverage Ratio-0.3457Theta-0.0012Rho-19.25Eff Leverage0.0191Vega
Intraday
- 5D
- Daily
News
Notable Earnings After Wednesday's Close
Cohen & Steers Q2 2024 Earnings Preview
Bluerock Hires Alternatives Industry Veteran Julia Phillips as Chief Marketing Officer
NEW YORK, July 16, 2024 /PRNewswire/ -- Bluerock announced today that it has hired industry veteran Julia Phillips to serve as Managing Director and Chief Marketing Officer. In this newly created
Cohen & Steers Is Maintained at Sell by UBS
Cohen & Steers Is Maintained at Sell by
UBS Maintains Sell on Cohen & Steers, Lowers Price Target to $63
UBS analyst Adam Beatty maintains Cohen & Steers (NYSE:CNS) with a Sell and lowers the price target from $65 to $63.
Cohen & Steers Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 -12.78% UBS $65 → $63 Maintains Sell 04/12/2024 -7.24% UBS $69 → $67 Maintains Sell 03/08/2024
Comments
2
Wednesday 7/17/24 Earnings Calls. I tagged a few, not all. 📊⚡️📊
$Tesla(TSLA.US$ $ASML Holding(ASML.US$ $First Bancorp(FNLC.US$ $Old Second Bancorp(OSBC.US$ $Kinder Morgan(KMI.US$ $Johnson & Johnson(JNJ.US$ $Netflix(NFLX.US$ $Monarch Casino & Resort(MCRI.US$ $Anew Medical(WENA.US$ $Cohen & Steers(CNS.US$ $SL Green Realty(SLG.US$ $Monarch Casino & Resort(MCRI.US$ $First Industrial Realty Trust Inc(FR.US$ $Alcoa(AA.US$ $Las Vegas Sands(LVS.US$ $Canfor Pulp Products Inc(CFX.CA$
$Tesla(TSLA.US$ $ASML Holding(ASML.US$ $First Bancorp(FNLC.US$ $Old Second Bancorp(OSBC.US$ $Kinder Morgan(KMI.US$ $Johnson & Johnson(JNJ.US$ $Netflix(NFLX.US$ $Monarch Casino & Resort(MCRI.US$ $Anew Medical(WENA.US$ $Cohen & Steers(CNS.US$ $SL Green Realty(SLG.US$ $Monarch Casino & Resort(MCRI.US$ $First Industrial Realty Trust Inc(FR.US$ $Alcoa(AA.US$ $Las Vegas Sands(LVS.US$ $Canfor Pulp Products Inc(CFX.CA$
+2
2
1
Investor concerns grow over Cohen & Steers' high P/E ratio in relation to dwindling earnings and low predicted growth rate. Speculations suggest the excessive P/E ratio is driven by investor confidence in a business turnaround which may not be sustainable given current earnings and growth rates.
An insider selling shares at a price lower than market value could reflect their belief in a fair lower price. Absence of purchases in the past year despite high insider ownership might cause concern. Usually, however, a high level of insider ownership is seen positively as it implies management's alignment with shareholder interests.
Gapping up
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
6
Read more